Drug intelligence / Profile preview

ulacamten

Development stage: Unknown
Lead developer: Cytokinetics
Modality: Small Molecules
Administration: Oral

Overview

Ulacamten (CK-586) is a selective, small-molecule cardiac myosin inhibitor developed by Cytokinetics for the treatment of heart failure with preserved ejection fraction (HFpEF). It functions as a negative allosteric modulator of cardiac myosin, reducing the number of myosin-actin cross-bridges that form during contraction. This mechanism targets the myocardial hypercontractility and impaired relaxation that are hallmarks of HFpEF. Ulacamten is currently in Phase 2 clinical development, with the AMBER-HFpEF trial evaluating its safety and efficacy in patients with this condition.

Other names: acamtenulacamten

Targets

MYH7 (Cardiac beta-myosin heavy chain)

Beyond the preview

Go deeper on ulacamten.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ulacamten.

Explore the full profile